Page 99 - Sitomegalovirüs Tanı, Tedavi Uzlaşı Raporu

Dis. 2014;16(6):1032-8.
76. Kim JH, Goulston C, Sanders S, Lampas M, Zangari M, Tricot G, Hanson KE.
Cytomegalovirus reactivation following autologous peripheral blood stem cell
transplantation for multiple myeloma in the era of novel chemotherapeutics and
tandem transplantation. Biol Blood Marrow Transplant. 2012;18(11):1753-8.
77. Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, et al.
Management of cytomegalovirus infection in haemopoietic stem cell transplantation.
Br J Haematol. 2013;162(1):25-39.
78. ECIL 7 CMV update. http://www.ecil-leukaemia.com/telechargements/ECIL-
7%20CMV%20final%20slides.pdf
79. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. Evaluation of
intervention strategy based on CMV-specific immune responses after allogeneic SCT.
Bone Marrow Transplant. 2007;40(9):865-9.
80. Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW. Measurement of human
cytomegalovirus loads by quantitative real-time PCR for monitoring clinical
intervention in transplant recipients. J Clin Microbiol. 2003;41(1):187-91.
81. Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison
of real-time PCR and pp65 antigen assays for monitoring the development of
Cytomegalovirus disease in recipients of solid organ and bone marrow transplants.
New Microbiol. 2011;34(2):157-64.
82. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and
clinical applications. Clin Microbiol Rev. 1998;11:533-554.
83. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus
infection and disease after allogeneic marrow transplantation. N Engl J Med.
1988;318:70-75.
84. Prentice HG, Gluckman E, Powles RL, et al. Impact of long- term acyclovir on
cytomegalovirus infection and survival after allogeneic bone marrow transplantation.
European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749-753.
85. Ljungman P, De La Camara R, Milpied N, et al. Randomized study of valacyclovir as
prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone
marrow transplants. Blood. 2002;99:3050-3056.
86. Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, et al.
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for
prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol
Blood Marrow Transplant. 2012;18(11):1687-99.
87. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell
transplant recipients. Blood. 2009;113(23):5711-9.
88. van der Heiden PLJ, Kalpoe JS, Barge RM, et al. Oral valganciclovir as pre-emptive
therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous
ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant.
2006;37:693-698.
89. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C,
Link H, Ljungman P; Infectious Diseases Working Party of the European Group for
Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus
ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem
cell transplantation. Blood. 2002;99(4):1159-64.
90. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H,

96